Guideline for Management of Significant Peripheral Arterial Disease in the Proximal Superficial Femoral Arteries

Initial Clinical Assessment

Significant PAD in the proximal superficial femoral artery (SFA) identified on CT must be correlated immediately with the patient’s symptom status (asymptomatic, claudication, or chronic limb‑threatening ischemia) because treatment pathways differ markedly. American College of Cardiology recommendation. [1][2]
Asymptomatic disease does not merit any endovascular or surgical intervention; prophylactic revascularization is contraindicated. American College of Cardiology guideline. 3
Intermittent claudication is defined as fatigue, cramping, or leg pain that begins with walking and resolves with rest within roughly 10 minutes. American College of Cardiology definition. 4
Chronic limb‑threatening ischemia (CLTI) is characterized by ischemic rest pain lasting >2 weeks, non‑healing ulcers, or gangrene. American College of Cardiology and European Society of Cardiology definitions. [4][5]
Perform a comprehensive pulse examination and direct foot inspection with shoes and socks removed; document femoral, popliteal, dorsalis pedis, and posterior tibial pulses bilaterally. American College of Cardiology protocol. 6

Statin therapy is recommended to improve walking distance in claudication and to lower cardiovascular event rates. European Society of Cardiology and American College of Cardiology guidance. [7][8]
Blood‑pressure control using ACE inhibitors, calcium‑channel blockers, β‑blockers, or diuretics as needed. European Society of Cardiology recommendation. 7
Diabetes management with optimal glycaemic control, especially in patients with CLTI. European Society of Cardiology and American College of Cardiology guidance. [7][5]

Prior to any revascularization, initiate medical therapy (statin, antiplatelet, cilostazol) and a supervised exercise program (30–45 min, 3 times/week, ≥12 weeks). American College of Cardiology recommendation. [1][2]
Cilostazol should be administered for at least 3 months to increase absolute claudication distance. American College of Cardiology recommendation. [1][2]
Revascularization is indicated only when all of the following are met:
American College of Cardiology criteria. [3][6]8
SFA lesion‑specific strategy:
- Short lesions (< 25 cm): Endovascular‑first approach is preferred. European Society of Cardiology guideline. 7
- Long lesions (≥ 25 cm): Bypass surgery is indicated when an autologous vein conduit is available, the patient is not high‑risk surgically, and life expectancy exceeds 2 years. European Society of Cardiology guideline. 7
Primary stent placement in the femoral artery is not recommended; stents may be used only as salvage therapy for suboptimal balloon dilation (persistent pressure gradient, residual stenosis > 50 %, or flow‑limiting dissection). American College of Cardiology recommendation. 3

Expedited evaluation and revascularization are mandatory for limb salvage. American College of Cardiology and European Society of Cardiology recommendation. [6][5]
Revascularization should be performed as soon as technically feasible. European Society of Cardiology recommendation. 5
Management must be coordinated by a multidisciplinary vascular team. European Society of Cardiology recommendation. 5
Pre‑operative cardiovascular risk assessment is required before any open surgical repair. American College of Cardiology guideline. 6
Initiate systemic antibiotics promptly if skin ulcerations show evidence of infection. American College of Cardiology recommendation. 6
Refer patients to providers with specialized wound‑care expertise. American College of Cardiology recommendation. 6
Isolated SFA lesions rarely cause CLTI; disease is usually multilevel. European Society of Cardiology observation. 5
Revascularization strategy must address all hemodynamically significant lesions. European Society of Cardiology recommendation. 7
Autologous saphenous vein is the conduit of choice for femoral‑popliteal bypass. European Society of Cardiology guideline. 7

No revascularization is indicated; care consists of:
- Aggressive risk‑factor modification (statin, blood‑pressure control, diabetes management). American College of Cardiology and European Society of Cardiology guidance. [3][8]7
- Regular surveillance with ankle‑brachial index (ABI) measurements. European Society of Cardiology recommendation. 7
- Patient education regarding symptom recognition. European Society of Cardiology recommendation. 7

After successful CLTI treatment, patients should be evaluated at least twice yearly by a vascular specialist because of high recurrence risk. American College of Cardiology recommendation. 6
Patients at risk for CLTI (ABI < 0.4 with diabetes, or any diabetic with known PAD) require regular foot inspection to detect early signs. American College of Cardiology recommendation. 6
Direct foot examination with shoes and socks removed should be performed at regular intervals. American College of Cardiology protocol. 6

Do not perform prophylactic revascularization in asymptomatic patients. American College of Cardiology contraindication. 3
Do not use primary stenting in the SFA except as salvage therapy. American College of Cardiology contraindication. 3
Do not proceed to revascularization for claudication without documented failure of supervised exercise and optimal medical therapy. American College of Cardiology warning. [1][2]
Do not delay revascularization in CLTI; expedited treatment is essential for limb salvage. American College of Cardiology and European Society of Cardiology warning. [6][5]
Surgical intervention is not indicated solely to prevent progression to limb‑threatening ischemia in patients with intermittent claudication. American College of Cardiology statement. 3